U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Curated SPACs News
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis